Senseonics Holdings, Inc.

Senseonics Holdings, Inc.

Senseonics Holdings, Inc.

Overview
Date Founded

2015

Headquarters

20451 Seneca Meadows Parkway, Germantown, MD, 20876-7005, USA

Type of Company

Public

Employees (Worldwide)

192

Industries

Medical Products & Equipment
Electrical Products

Company Description

Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Contact Data
Trying to get in touch with decision makers at Senseonics Holdings, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial & Accounting Officer

Chief Operating Officer

Chief Medical Officer

Vice President & General Manager, US Region

Vice President & General Manager, Global Commercial Operations

Vice President-Engineering, Research & Development

Vice President-Clinical Sciences

Human Resource Manager

Investor Relations Contact

Board of Directors

Partner at Lindsay Goldberg, LLC

Partner, Healthcare at New Enterprise Associates

President & Chief Executive Officer at Senseonics Holdings, Inc.

Founder at Taking Control of Your Diabetes

Former Executive Vice President of Finance & Chief Financial Officer at Nordion (Canada), Inc.

Managing Partner at Delphi Ventures, Inc.

Chairman & Chief Executive Officer at TerSera Therapeutics LLC

Paths to Senseonics Holdings, Inc.
Potential Connections via
Relationship Science
You
Senseonics Holdings, Inc.
Owners & Shareholders
Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Details Hidden

Overview Leadership Balancing innovative strategy with careful risk management to deliver strong performance. Overview While our investment strategies are innovative, capital preservation and strict risk management are paramount. A number of unique characteristics define III Offshore Advisors, and set us apart within the global investment management industry: We are long-term investors with a 30-year history. While our investment strategies are innovative, capital preservation and strict risk management are paramount. We operate on a consensus management basis, obligating our trading principals to reach an agreement on all new trading strategies prior to implementation. Our team consists of exceptional individuals, many hailing from top-tier institutions such as The Wharton School, MIT, Cambridge (UK), Yale and Harvard Universities. A solid and stable platform enables us to attract such talent, and offer our clients rich intellectual resources. Staying on top of the latest technology is a priority at III. In fact, our trading systems and analytics are developed almost exclusively in-house, giving us a better understanding and freeing us from the limitations of generic software and from dependence on systems providers.

Details Hidden

Overview Leadership Balancing innovative strategy with careful risk management to deliver strong performance. Overview While our investment strategies are innovative, capital preservation and strict risk management are paramount. A number of unique characteristics define III Offshore Advisors, and set us apart within the global investment management industry: We are long-term investors with a 30-year history. While our investment strategies are innovative, capital preservation and strict risk management are paramount. We operate on a consensus management basis, obligating our trading principals to reach an agreement on all new trading strategies prior to implementation. Our team consists of exceptional individuals, many hailing from top-tier institutions such as The Wharton School, MIT, Cambridge (UK), Yale and Harvard Universities. A solid and stable platform enables us to attract such talent, and offer our clients rich intellectual resources. Staying on top of the latest technology is a priority at III. In fact, our trading systems and analytics are developed almost exclusively in-house, giving us a better understanding and freeing us from the limitations of generic software and from dependence on systems providers.

Recent Transactions
Details Hidden

Senseonics Holdings, Inc. issued . USD Common Stock

Details Hidden

Senseonics Holdings, Inc. issued . USD Common Stock

Details Hidden

Senseonics Holdings, Inc. issued . USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onSenseonics Holdings, Inc. issued . USD Common Stock

Legal Advisor

Advised onSenseonics Holdings, Inc. issued . USD Common Stock

Underwriter

Advised onSenseonics Holdings, Inc. issued . USD Common Stock

Legal Advisor

Advised onSenseonics Holdings, Inc. issued Common Stock

Legal Advisor

Advised onSenseonics Holdings, Inc. issued Common Stock

Legal Advisor

Advised onSenseonics Holdings, Inc. issued Common Stock

Advisors & Consultants
Advisor

Chief Financial Officer at Lyra Therapeutics, Inc.

Clients

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Indutrade AB engages in the development, marketing, and sale of components, systems, and services. It operates through the following segments: Benelux, DACH, Finland, Flow Technology (FT), Fluids and Mechanical Solutions (FMS), Industrial Components (IC), Measurement and Sensor Technology (MST), UK, and Others. The Benelux segment offers valves, hydraulic and industrial equipment, measurement technology, and automation products. The DACH segment includes valves, construction material, and hydraulic and industrial equipment. The Finland segment consists of hydraulics and industrial equipment to measurement technology, valves, service, filters, and process technology. The FT segment comprises valves, pipes and pipe systems, measurement technology, pumps, and hydraulics and industrial equipment. The FMS segment provides filters, hydraulics, tools and transmission, industrial springs, valves, water and wastewater fittings, steel profiles, compressors, folding and movable walls, product labelling, and construction plastics. The IC segment offers hydraulics and industrial equipment, chemical technology, and fasteners. The MST segment focuses on the manufacturing industries like electronics, vehicles, and energy. The UK segment provides springs, piston rings, press work, valve channels, pipes, and pipe systems. The Others segment refers to the parent company. The company was founded in 1978 and is headquartered in Kista, Sweden.

Key Stats and Financials As of 2018
Market Capitalization
$184M
Total Enterprise Value
$322M
Earnings Per Share
$-0.6
Revenue
$18.9M
Net Profit
$-94M
EBITDA
$-87.3M
EBITDAMargin
-461.63%
Total Debt
$50.9M
Total Equity
$71.3M
Enterprise Value Sales
17.02x
TEVNet Income
-3.42x
Debt TEV
0.16x
Three Year Compounded Annual Growth Rate Of Revenue
692.47%
Competitors
Abbott Laboratories Pharmaceuticals - Abbott Park, Illinois

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Medtronic Plc Medical Products & Equipment - Dublin, DU

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Senseonics Holdings, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Senseonics Holdings, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Senseonics Holdings, Inc..